visibl ep
struggl limit long-term growth recent multipl
expans seem alreadi reflect improv cost/pric
solid result share trade flat post stronger
expect result top-line upsid organ sale
consensu oper profit beat net post clearli fy visibl
increas allud call commod moder
strong price place ep estim move
rais price target base
price-to-earnings vs prior reflect near-term visibl higher stapl
multipl high level realiz strong price solid categori
price look better posit hit upper half fy guidanc
beat remain ew given still weak market share perform
recent multipl expans alreadi reflect improv cost/pric
top-line detail top-line upsid broad-bas north america consum
product emerg market organ sale north america
organ sale consum product person
consum tissu k-c profession na person
volum babi lsd adult dd
upcom summer innov plan emphas call includ premium
huggi diaper pois pad na consum tissu price increas
off-set volum declin call lower
promot activ less sever flu season compar last year top-line
upsid led strong perform emerg market y-o-i
average vs average average
growth argentina worth bp total organ sale
growth vs like bp organ sale growth brazil
driven higher sell price volum remain sluggish china organ
sale -hsd huggi diaper impact competit price
reduct emerg market region strong organ sale
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
growth eastern europ organ sale growth asean behind
strength huggi vietnam
margin detail commod front commod came better
expect bp gross margin impact vs bp mse call
hint wiggl room fiscal year commod price
lsd fluff -lsd recycl fiber superabsorb rel flat
reiter outlook commod headwind
includ headwind save quarter came
compani indic still track fy guidanc
ep ep consensu mse
organ sale growth posit surpris price mix
volum consensu mse key north america
consum busi organ growth develop emerg
market top-line upsid augment bp gross margin beat
bp yoy vs bp consensu lead gross profit upsid vs
consensu solid price gross profit upsid partial off-set
higher expect mr sg bp yoy vs bp
consensu oper margin flat yoy bp bp
consensu oper profit consensu line lower
interest expens ad cent versu model lower tax rate ad
cent advertis spend also y-o-i repurchas
share share outstand averag price in-lin
expect weak vs mse vs
year ago period driven larg work capit drag elev capital-expenditure
in-lin expect higher work capit time
payables/receiv inventori build relat restructur
increas restructur cash payment reiter guidanc
oper cash flow slightli y-o-i vs
segment result segment person organ sale vs
mse consum tissu flat vs mse k-c profession
vs mse region basi person organ sale
north america develop emerg market
price mix volum flat develop market ex-north
america consum tissu organ sale north america price
volum difficult comparison impact
price increas develop emerg market price mix
volum develop market ex-north america
ep organ sale guidanc reiter reiter
ep guidanc rang bracket prior consensu ep
weight higher comfort upper half
rang beat also reiter guidanc individu line
remain equal-weight strong start year achiev fy guidanc
unchang despit upsid remain equal-weight
think valuat price-to-earnings ev/ebitda ev/ebitda
discount peer pg/cl/chd/clx appropri reflect market share
challeng limit lt top-line potenti vs peer
need better visibl move toward attract bull case return
need better visibl move toward attract bull case return
pt reflect base case assumpt
price pass-through weaker-than-expect commod drive margin
upsid innovation/trad privat label drive volum upsid
bp price off-set commod lower fear bp
volum upsid trade up/new product usd weaken valuat
expand ep standard deviat last average
modest top-line rebound organ sale growth rebound
oper profit margin expand bp driven
commod cost fx cost save price benefit valuat
ep slightli histor averag ntm price-to-earnings
price strong expect pg/pl pressur volum share
loss input cost ramp competit pressur increas drive
price bp volum bp forecast commod cost add
bp oper margin downsid usd strengthen valuat contract
ep slightli last average
exhibit bear bull price commod cut driver
valu
project long-term organ revenu growth
in-lin downwardli
revis guidanc prior
driven competit concern
pg/privat label pressur north america
profit local compani pressur
china also see mute categori growth
declin birth rate us/develop
contrast concern neg
ep revis view ep
guidanc achiev post strong
result furthermor detail profit build
point flexibl less oner
commod inflat increment price
fundament trade
stock perform view kmb price-to-earnings
pg/cl/chd/clx discount vs
pg/cl appropri consid
risk achiev price
upsid risk includ lower expect
share trend greater price realiz
downsid risk includ greater
price realiz cost-cut downsid
product sold
sale
sale bp chang
sale
sale bp chang
incom equiti interest
net incom equiti compani
net incom non-controlling interest
cash equival
invest equiti compani
redeem prefer common secur sub
depreci amort
increas decreas oper work capit
net loss asset disposit
equiti compani earn excess dividend
provid oper
acquisit busi net
proce sale invest
proce disposit properti
net chang time deposit
use invest
net increas decreas short-term debt
net increas decreas long-term debt
proce exercis stock option
purchas treasuri share
use financ
provid discontinu oper
effect exchang rate
net increas decreas
equiv beg
equiv end
